Bilirubin metabolism
Haem is an important component not only of haemoglobin but also of many of the respiratory enzymes, including the cytochromes. Rece~tly it~as been shown that haem represses mammalian ammo laevulinic acid synthetase (Marver, Schmid and Schutzel, 1968) , which is the rate limiting enzyme in its biosynthesis; a mechanism for the elimination of haem is, therefore, essential. Intact haem is not, however, readily excreted, and its elimination is achieved mainly by conversion to bilirubin and excretion as bilirubin glucuronide, in the bile. Although it has been shown that physiological amounts of 14C haem can be rapidly converted to 14C bilirubin the precise mechanisms employed are still uncertain (Fig. 1) . It is known that the opening of the IX-methene bridge is accompanied by the formation of one molecule of carbon monoxide, and its rate of expiration has been used clinically as an index of haem catabolism (Coburn, Williams and Kahn, 1966) . Controversy, however, exists around the question as to whether the IX-methene bridge of the protoporphyrin ring of haem is split before or after the removal of the globin and iron moieties from haemoglobin.
Haem is degraded in the reticulo-endothelial system mainly in the liver and spleen. The process is probably enzymatic rather than a simple chemical oxidation as 'in vitro' experiments have suggested. Nakajima and his colleagues (1963) proposed that a soluble cytoplasmic enzyme called 'haem IX-methenyl oxygenase' was involved, but this postulate has not found general acceptance since the system does not work with haem, and only with haemoglobin if it is bound to haptoglobin. Gray and Nakajima (1969) have since described a mitochondrial enzyme in the spleen which is capable of forming bile pigments from haem. Tenhunen, Marver and Schmid (1968) , on the other hand, have provided evidence which demonstrates there is a microsomal enzyme 'haem oxygenase' in rat spleen and liver which aerobic~lly converts haem to bilirubin with the intermediate formation of biliverdin. This enzyme is heat labile NADPH dependent and the reaction is inhibited by carbon monoxide; its properties therefore closely resemble those enzymatic systems which are involved in the detoxication of drugs and endogenous meta-Paper read at Southern EDiland and South Wales Reaional Mectina. LondoD, July, 1969.
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Hematin + globin haemoglobin. Me = methyl, P = proprionic acid, V = vinyl catabolism of haemoglobin need not necessarily involve bilirubin and that other, at present unknown, end-products may be formed. Isotopic studies involving the administration of labelled bilirubin precursors, glycine and delta-amino laevulinic acid (ALA), and the subsequent isolation of bilirubin from the plasma or stercobilin (an intestinal oxidation product of bilirubin) from the faeces have established that in the normal subject 10 to 20 %of newly synthesized bilirubin is derived from sources other than the mature circulating red cell (London, Shemin, West and Rittenberg, 1949; Gray, Neuberger and Sneath, 1950) . The 'early labelled bilirubin' has two major components, one of which is related to erythropoiesis while the other is not (Yamamoto, etal., 1965; Robinson,1968) . The nonerythropoietic component can be demonstrated by the administration of ALA, since this precursor of bilirubin is not readily incorporated into haemoglobin haem; it appears to be synthesized mainly in the liver and to be derived from 'free haem' or its precursors, as well as non-haemoglobin haem-eontaining proteins such as myoglobin, catalase, tryptophane pyrollase, and the cytochromes (Levitt, et al., 1968) . The extent to which formation of this type of 'early bilirubin' is increased in jaundice has not been fully investigated; so far, raised values have only been reported in pernicious anaemia, congenital erythropoietic porphyria and in the Crigler-Najjar syndrome. The erythropoietic component of early labelled bilirubin is probably formed mainly in the spleen and bone marrow, and is increased in haematological disorders characterised by ineffective erythropoiesis, such as thalassemia, dyserythropoietic jaundice (originally called shunt hyperbilirubinaemia, by Israels and colleagues) and congenital porphyria.
Unconjugated bilirubin is lipid soluble and has only a very limited solubility in aqueous solutions at a physiological pH. It does, however, bind tightly to albumin and in this form is transported in the plasma (Ostrow, Schmid and Samuelson, 1963) . Each molecule of albumin is capable of binding at least 2 molecules of bilirubin, so that theoretically, a maximum concentration of 80 mg/1oo ml could be achieved in plasma; in addition, small quantities of pigment may be bound to the Il-globulins if the plasma bilirubin concentration exceeds 20 to 30 mg/loo ml. The binding capacity of albumin for bilirubin can be modified by anionic compounds such as sulphonamides, salicylates and free fatty acids, which are bound by plasma and compete with bilirubin for binding sites (Johnson, et al., 1959) . The administration of these drugs to pregnant women or the neonate may increase the risk of kernicterus in the jaundiced infant, since the 'free bilirubin' will cross the blood brain barrier, which appears to be more permeable in the newborn than the adult. Asphyxia, hypoxia and acidosis may also interfere with bilirubin-albumin binding (Diamond and Schmid, 1966) , as well as increase the permeability of the brain for unconjugated bilirubin.
The liver appears to have a selective capacity to remove unconjugated bilirubin and other organic anions very rapidly from the plasma. In this process the unconjugated bilirubin becomes dissociated from albumin at the plasma membrane, which is permeable to non-polar molecules, and specific intracellular proteins act as acceptors and facilitate the transfer of bilirubin into the cell (Fig. 2 ). Levi (l969b) have isolated 2 such proteins (designated Y and Z) from the liver cytoplasm, which are not albumin and which appear to account for most of the intracellular binding of bilirubin, as well as bromosulphthalein (BSP) when this is administered. Drugs such as ftavaspidic acid (male fern oil) and bunamiodyl (a cholecystographic contrast medium) which may cause retention of unconjugated bilirubin and BSP, interfere stoichiometrically with their binding to the Z protein but not to the Y protein. It has also been shown that the development of the Y protein in guinea pigs is retarded at birth and that in the adult animal its production can be enhanced by treatment with phenobarbitone. Whether a deficiency of this protein is an important factor in the aetiology of neonatal jaundice has not, however, yet been established (Levi, Gatmaiten and Arias, 1969a) . The conversion of bilirubin to a polar compound is essential for the biliary excretion of bilirubin. This is achieved mainly by esterification of the two carboxyl groups on the bilirubin molecule to form the diglucuronide. The specific conjugating enzyme, bilirubin-UDP-glucuronyl-transferase, is located in the smooth endoplasmic reticulum of the liver cells, and uridine diphosphate glucuronic acid acts as the glucuronyl donor. Other conjugates, including the sulphate, have been detected in bile, but it would appear that they are oflimited functional importance since they do not serve as an alternate pathway for bilirubin excretion where there is a congenital deficiency of bilirubin glucuronyl transferase.
After conjugation with glucuronic acid, bilirubin is rapidly excreted by the liver cell against a large concentration gradient. This active transport system is common to many organic anions including BSP but not to conjugated bile acids and is probably carrier-mediated and energy-dependent. Excretion in the bile occurs in the form of a micellar complex with cholesterol, phospholipids and bile salts.
Combination with glucuronic acid increases the polarity and size of the pigment molecule, and consequently bilirubin is not appreciably reabsorbed from the intestine or the gallbladder. In man, the bilirubin glucuronide ester linkage probably remains intact during transit through the small bowel. Bacterial,B-glucuronidases present in the large bowel partially or completely hydrolyse the pigment to unconjugated bilirubin which is then immediately reduced to urobilinogen, in which form it appears in the faeces. Some of the urobilinogen (which is the generic name for an entire class of colourless tetrapyrrolic metabolites which form a purple complex with p-dimethylaminobenzaldehyde (Erlich's reagent) is oxidised on standing in air to pigmented urobilins; these pigments are not, however, responsible for the colour of the faeces .
Urobilinogen may be absorbed and then re-excreted by the liver and kidney. Its appearance in the urine will be dependent on the bile pigment output and the site of the urobilinogen-forming bacteria, since urobilinogen is more efficiently absorbed from the small intestine than the colon. In hepatocellular disease increased amounts of urobilinogen will remain in the systemic circulation and therefore be available for renal excretion. In addition the amount of pigment appearing in the urine will depend on the state of hydration of the patient and the urine pH, the highest clearance values being obtained when the 71 urine is alkaline and is collected between 2 p.m. and 4 p.m. (Watson, 1963 and Lester and Troxler, 1969) .
Since the unconjugated bilirubin-albumin complex cannot cross the glomerulus, bilirubin is not found in normal urine; in obstructive jaundice a different situation pertains since approximately 1% of the bilirubin-glucuronide-albumin complex in the plasma is dialysable and can therefore be excreted by glomerular filtration (Fulop, Sandson and Brazeau, 1965) . It seems unlikely that tubular secretion or non-ionic diffusion are of importance in the renal excretion of bilirubin but tubular re-absorption may be involved (Ali and Billing, 1966) .
Jaundice
It is well known that increased concentrations of conjugated bilirubin are associated with jaundice caused by extra-hepatic obstruction (e.g. gall stones or carcinoma of the pancreas), intrahepatic obstruction due to impaired secretion of bilirubin (e.g, Dubin-Johnson syndrome), intrahepatic cholestasis (e.g. primary biliary cirrhosis, biliary atresia, drugs such as chlorpromazine or steroids, and jaundice of pregnancy) or hepatocellular damage (e.g, drug or viral hepatitis and cirrhosis). Raised concentrations of unconjugated bilirubin would, however, suggest that there is an overproduction of bilirubin, a defect in hepatic uptake or an impairment in conjugation.
At the present time there is unfortunately no simple method available which is specific for unconjugated bilirubin and an estimate of its concentration in plasma can only be obtained by determining the difference between the values obtained for 'total' and 'conjugated' (direct reacting) bilirubin. The value obtained will depend on the conditions chosen for the determination of conjugated bilirubin and will probably be an under-estimate as in most methods the unconjugated bilirubin makes a small contribution to the 'direct reading' in the van der Bergh reaction. In spite of these methodological problems useful diagnostic information can be given to the clinician if it is known that the jaundice is due to an accumulation of unconjugated bilirubin rather than conjugated bilirubin in the plasma. Using the Michaelsson method (Michaelsson, Nosslin and Sjolin, 1965) , we have found that the upper limit of normal for total bilirubin is 0.8 mg/loo mI whereas that for conjugated bilirubin is 0.3 mg/loo ml. We have, therefore, arbitrarily chosen to describe a jaundice as an unconjugated hyperbilirubinaemia if the serum total bilirubin concentration is 1 mg/loo mI or greater and 85% or more of the pigment is present as unconjugated bilirubin.
Unconjugated kyperbilirubinaemia
In haemolytic disease the normal capacity of the liver to excrete bilirubin can be exceeded; this may not occur, however, until there is a four-fold increase or more in the normal rate of break-down of the red cells. In approximately 15% of cases there may also be some accompanying liver disease with resulting impairment in excretion, so that conjugated as well as unconjugated bilirubin will accumulate in the blood. In erythropoietic disorders, as has been previously mentioned, a proportion of the bilirubin that accumulates will have come from the increased production of 'early bilirubin'; it is, however, beyond the scope of a routine laboratory to determine the origin of the plasma bilirubin.
Our understanding of the 'uptake mechanism' of bilirubin is still rudimentary, but there is indirect evidence to suggest that this may be defective in some pathological conditions such as Gilbert's syndrome. Certain drugs, including the cholecystographic drugs (Bolt, et al., 1961) . flavispidic acid (male fern oil) and the antibiotic rifampicin have been shown to interfere in this process; possibly by competing for intra-hepatic binding sites. The antibiotic novobiocin, on the other hand, causes jaundice by competitive inhibition of bilirubin-UDP-glucuronyl transferase (Hargreaves and Holton, 1960) . Mild fluctuations in plasma bilirubin can often be explained by a knowledge of previous drug administration and may not necessarily be due to laboratory errors.
.A deficiency of bilirubin UDP-glucuronyl transferase is probably the commonest cause of unconjugated hyperbilirubinaemia. In the neonate, levels of the enzyme are reduced, particularly in the premature infant. This situation is largely responsible for-'physiological jaundice of the newborn' and explains the very high levels of plasma bilirubin encountered in haemolytic disease due to rhesus or ABO incompatibility. In the large majority of cases maturation of the enzyme quickly occurs, so that bilirubincan be excreted as the glucuronide into the bile. In very rare cases bilirubin-UDP-glucuronyl transferase deficiency persists into adult life and the patient remains severely jaundiced with levels of serum unconjugated bilirubin which may be as high as 30-40 mg/loo ml (Crigler-Najjar syndrome); bilirubin production, standard liver function tests and liver histology are normal. Isotope studies have shown that a steady serum bilirubin concentration is probably achieved by catabolism of the pigment to unidentified derivatives in bile and excretion of bilirubin across the intestinal wall (Schmid and Hammaker, 1963) .
The glucuronide conjugating capacity of the liver can be enhanced by the administration of drugs, such as phenobarbitone, which will cause induction of microsomal enzymes. Such treatment may be used to reduce the jaundice of the majority of patients with idiopathic unconjugated hyperbilirubinaemia. In the more severely affected patients with the Crigler-Najjar syndrome, whose bile is essentially colourless, and who presumably have an absolute deficiency of the enzyme, no beneficial effect is obtained with phenobarbitone (Arias, et al., 1969) .
Phenobarbitone has also been used to induce glucuronyl transferase activity in the newborn and there have been several reports that the incidence of neonatal jaundice can be reduced by administration of this drug, particularly if it is given to the mother shortly before birth (Rambouer, Thompson and Williams, 1969) . Another form of preventive treatment which has been much discussed recently is irradiation with blue light (peak emission 450-480 nm). This simple procedure has proved to be beneficial in infants whose serum bilirubin is rising slowly (e.g. in premature infants) but should not be considered for infants with severe haemolytic disease. At present there is no direct evidence that the products of bilirubin catabolism by blue light are toxic (Broughton, et al., 1965) , but until our understanding of the mechanisms involved are better understood it is unlikely that this form of therapy will find general acceptance by pediatricians (Lucey, 1969) .
Raised levels of unconjugated bilirubin (1--4 mg/loo ml), in the absence of overt haemolysis, may accompany a number of disease states such as cardiac disease, fatty liver and alcoholism, biliary tract disease, cirrhosis, malignant tumors, thyrotoxicosis and infections. Unconjugated hyperbilirubinaemia can follow viral hepatitis; it may also occur in those living at high altitudes. When these acquired conditions have been excluded a diagnosis of idiopathic unconjugated hyperbilirubinaemia, which has been called Gilbert's syndrome (or constitutional hepatic dysfunction) has to be considered (Powell, 1967) .
Scleral icterus is the only abnormal physical finding in patients with Gilbert's syndrome although they often present with other complaints and their jaundice is an incidental finding. The serum bilirubin level may on occasions be normal and will be increased by fatigue, emotional tension, menstruation, alcohol, and starvation. Apart from an impaired bilirubin tolerance, hepatic function tests (including BSP) are normal. No abnormalities in histology with light microscopy are detected and the patients have no evidence of overt haemolysis although 50%have slightly reduced red cell survival times. The increased bilirubin production resulting from this low grade haemolysis is not in itself sufficient to produce hyperbilirubinaemia in a normal subject and the 0 
CONCLUSION
A knowledge of the type of bilirubin accumulating in the blood of an icteric patient may help to elucidate the abnormality in bilirubin metabolism present (Fig. 4 ). An unconjugated hyperbilirubinaemia can be caused by an overproduction of bilirubin (haemolysis), defective hepatic uptake and transport of biliru bin, or impaired conjugation of bilirubin. If the dominant pigment is conjugated bilirubin then one can conclude that the jaundice is due to defective canalicular excretion or a mechanical block in the bile duct system. jaundice is more likely to be due to a reduction in UDP-bilirubin-glucuronyl transferase activity (Black and Billing, 1969) . A defective hepatic uptake of bilirubin has also been demonstrated.
Gilbert's syndrome is approximately four times as common in males as females and siblings are more frequently affected than parents. It is probably inherited as an autosomal dominant , but the heterogenous nature of the syndrome makes it difficult to establish the exact mode of inheritance (Fig. 3) . The frequency ofthe condition is unknown, but it may be as common as 0.5 % of the male population and could account for the skewed distribution of serum bilirubin levels reported for the normal population by some investigators (Wooton, 1964) . Since the prognosis of Gilbert's syndrome is excellent an awareness of these mild types of familial non-haemolytic unconjugated hyperbilirubinaemia is important since such a diagnosis will relieve a patient of the fear of 'liver disease' and may prevent an unnecessary operation.
